A
pioneering program when it began in 1987, the UPMC artificial
heart program has grown to be one of the largest programs
of its kind in the world. Unique in its collaboration with
the biomedical engineering program, it was the first in the
world to discharge patients from the hospital who were supported
with Left Ventricular Assist Devices. The program has provided
support to more than 200 patients with end- stage congestive
heart failure, achieving the equivalent of more than 45 years
of patient support days. Its full-time staff of two cardiac
surgeons, two nurse coordinators, five clinical engineers
and 25 part-time engineers is world renowned for expertise
in the utilization of both approved and developmental technology.
Through the program, inroads into the understanding of the complex interface between technology and biology, patient selection, best conditions for implantation, and the demands for outpatient care have been achieved. New methods for understanding the process of myocardial recovery have been developed using echocardiographic tools.
Most importantly, the lessons learned through the application of technology in the clinical arena have brought to light new challenges which can be taken back to the basic science and engineering laboratories for resolution. This iterative process is applicable to the field of regenerative medicine as a whole.
Finally, the program has become an invaluable global teaching resource, having developed an educational program for ventricular assist devices that has trained surgeons from more than 100 U.S. and international centers.